Treatment strategy of breast cancer using micro RNA-1290

• Project/Area Number: 15K10061
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: General surgery
• Research Institution: Nagoya City University
• Principal Investigator: Hato Yukari 名古屋市立大学, 大学院医学研究科, 研究員 (20721864)
• Co-Investigator(Kenkyū-buntansha): 遠山 竜也 名古屋市立大学, 大学院医学研究科, 教授 (30315882) ; 吉本 信保 名古屋市立大学, 大学院医学研究科, 研究員 (10551244) ; 遠藤 友美 名古屋市立大学, 大学院医学研究科, 講師 (20566228)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000); Fiscal Year 2017: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
• Keywords: 乳癌 / miR-1290

Outline of Final Research Achievements

We investigated the correlations of miR-1290 and its target genes, NAT1 and FOXA1, with breast cancer prognosis. Positive correlation was observed between high NAT1 protein expression and better overall survival in breast cancer patients. Positive correlation was also observed between FOXA1 mRNA expression and disease-free survival in breast cancer patients who received neoadjuvant chemotherapy. However, no correlation was observed miR-1290 expression and prognosis in breast cancer patients.